Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

14 Mar 2022

Abstract excerpt

Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35335079
DOI: 10.3390/vaccines10030448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA VaccinePMID 35335079Read ↗

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipientsSemantic proximity Read ↗

B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant RecipientsSemantic proximity Read ↗

Humoral immune responses against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccineSemantic proximity Read ↗

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsSemantic proximity Read ↗

HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTSSemantic proximity Read ↗

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA VaccinesSemantic proximity Read ↗

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapySemantic proximity Read ↗

Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipientsSemantic proximity Read ↗

Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patientsSemantic proximity Read ↗

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 dosesSemantic proximity Read ↗

SARS-CoV-2 Vaccine Non-response among Hematopoietic Stem Cell Transplant Patients: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Cellular and Humoral Responses to SARS-CoV-2 Vaccination in Immunosuppressed PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.